Managing intellectual property rights over clinical trial data to promote access and benefit sharing in public health

IIC International Review of Intellectual Property and Competition Law

Volumn 44, Issue 2, 2013, Pages 140-177

  Andanda, Pamela ^a  

^a University of the Witwatersrand   (South Africa)

Author keywords

Benefit sharing; Clinical trials; Intellectual property; Public health; Test data; TRIPS Agreement

Indexed keywords

EID: 84876764536     PISSN: 00189855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s40319-012-0016-z     Document Type: Article

References (70)

1. Abbott FM (2006) The cycle of action and reaction: developments and trends in intellectual property and health. In: Roffe P, Tansey G, Vivas-Eugui D (eds) Negotiating health: intellectual property and access to medicines. Earthscan, London, p 27-40.
2. Ad Carvalho ECA, Batilana AP, Simkins J, Martins H, Shah J et al. (2010) Application description and policy model in collaborative environment for sharing of information on epidemiological and clinical research data sets. PLoS ONE 5(2):e9314. doi:10.1371/journal.pone.0009314 (2010).
3. Andanda P, Schroeder D, Chaturvedi S, Mengesha EH, Hodges TJ (2013) Legal frameworks for benefit sharing: from biodiversity to human genomics. In: Schroeder D, Cook-Lucas J (eds) Benefit sharing: a short handbook for users of biological resources. Springer, Netherlands.
4. Arkinstall J, Childs M, Menghaney L, Ford N, von Schoen-Angerer T (2011) The reality behind the rhetoric: how European policies risk harming access to generic medicines in developing countries. Journal of Generic Medicines 8:14-22.
5. Baker BK (2008) Ending drug registration apartheid: taming data exclusivity and patent/registration linkage. American Journal of Law & Medicine 34:303-344.
6. Banisar D (2006) Freedom of information around the world 2006: a global survey of access to government information laws. Privacy International 38.
7. Barra ACG, Albuquerque ID (2011) A decade of generic pharmaceutical policies in Brazil. Journal of Generic Medicines 2(8):72-75.
8. Biotechnology Industry Organisation (2012) 2012 special 301 submission to the Office of the United States Trade Representative. Docket No. USTR-2011-0021. available at http://www.bio.org/sites/default/files/ 2012%20BIO%20Submission.pdf.
9. Brownlie I (2003) Principles of public international law. Oxford University Press, New York.
10. Caplan AL, Curry DR (2007) Leveraging genetic resources or moral blackmail? Indonesia and Avian Flu Virus sample sharing. The American Journal of Bioethics 7(11):1-2.
11. Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. The Lancet 374(9692):86-89.
12. Chan AW, Hróbjartsson A, Haahr MT, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291:2457-2465.
13. Chokshi DA, Parker M, Kwiatkowskia DP (2006) Data sharing and intellectual property in a genomic epidemiology network: policies for large-scale research collaboration. Bulletin of the World Health Organization 84:382-387.
14. Correa CM (2002) Protection of data submitted for the registration of pharmaceuticals: implementing the standards of the TRIPS agreement. South Centre, Geneva.
15. Correa CM (2006) Protecting test data for pharmaceutical and agrochemical products under free trade agreements. In: Roffe P, Tansey G, Vivas-Eugui D (eds) Negotiating health: intellectual property and access to medicines. Earthscan, London, p 81-96.
16. Cottier T, Meitinger I (2000) The protection of test data submitted to governmental authorities: the impact of the TRIPS agreement on EC law. In: Meng W, Stein T (eds) Marketing authorization for pharmaceutical products and the protection of submitted data, p 53-72.
17. de Pastors A (1995) Supplementary protection certificates: situation after two years of operation of the ECI768/92 SPC Regulation. World Patent Information 17(3):189-192.
18. Di Blasi G (2009) Data exclusivity protection in Brazil. World Intellectual Property Review, November/December 32-35.
19. Di Masi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics 22:151-185.
20. Doshi P, Jefferson T, Del Mar. C (2012) The imperative to share clinical study reports: recommendations from the Tamifiu experience. PLoS Med 9(4):e1001201. doi:10.1371/journal.pmed.1001201.
21. Editorial (2012) Shining a light on trial data. Nature Biotechnology 30 (5).
22. Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G (2012) Open clinical trial data for all? A view from regulators. PLoS Med 9(4):e1001202. doi:10.1371/journal.pmed.1001202
23. Fellmeth AX (2004) Secrecy, monopoly, and access to pharmaceuticals in international trade law: protection of marketing approval data under the TRIPs agreement. Harvard International Law Journal 2(45):443-502.
24. Fidler DP (2001) 'Geographical Morality' revisited: international relations, international law and the controversy over placebo controlled HIV clinical trials in developing countries. Harvard International Law Journal 42(2):299-354.
25. Fidler DP (2008) Influenza virus samples, international law, and global health diplomacy. Emerging Infectious Diseases 14(1):88-94.
26. Fischmann F (2012) ANVISA v Lundbeck Brasil Ltda. IIC 43:217-221.
27. Fisher (2006) Clinical trials results databases: unanswered questions. Science 311:180-181.
28. Fujimoto A (2010) Tokyo High Court, 16 November 2007: JAPAN - Yakugai Ombudsperson Kaigi v. Ministry of Health, Labour and Welfare of Japan, "Iressa". IIC 41:616-619.
29. Gervais D (2008) The TRIPS Agreement: drafting history and analysis. 3rd edn. Sweet and Maxwell, London.
30. Gibson J (2009) Intellectual property, medicine and health: current debates. Ashgate Publishing Company, Surrey.
31. Godlee F (2012) Clinical trial data for all drugs in current use must be made available for independent scrutiny. British Medical Journal 345. doi: 10.1 l36/bmj.e7304.
32. Gotzsche PC (2011) Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 12(1):249. available at http://www.trialsjournal.com/content/12/l/249.
33. Hayden C (2007) Taking as giving: bioscience, exchange, and the politics of benefit-sharing. Social Studies of Science 37(5):729-758.
34. Health Canada (2005) Draft issue identification paper: registration and disclosure of clinical trial information. available at http://www.hc-sc.gc.ca/ dhp-mps/alt-formats/hpfb-dgpsa/pdf/prodpharma/draftiipctrd-June- ddeebaucheedecjuin-2005-eng.pdf.
35. Ho C (2011) Access to medicines in the global economy: international agreements in patents and related rights. Oxford University Press, Oxford.
36. Human D, Fluss SS (2001) The World Medical Association's Declaration of Helsinki: historical and contemporary perspectives, available at http://www.wma.net/en/20activities/10ethics/10helsinki/draft-historical- contemporary-perspectives.pdf.
37. Kent DM, Hayward RA, Griffith JL, Vijan S, Beshansky JR. Califf RM, Selker HP (2002) An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 113(2):104-111.
38. Leibowitz K, Sheckler V (2006) Negotiating clinical trial agreements. The Regulatory Affairs Journal (RAJ) Devices Sept/Oct. 289-292:289.
39. Lemmens T, Telfer C (2012) Access to information and the right to health: the human rights case for clinical trials transparency. American Journal of Law and Medicine 38(1):63-112.
40. Light DW, Lexchin J (2005) Foreign free riders and the high price of US medicines. British Medical Journal 331:958-960.
41. Lipkus NB, Mackie JE, Singer PA (2010) Guidance for reconciling patent rights and disclosure of findings at scientific meetings. Health Research Policy and Systems 8:15. available at http://www.health-policy-systems.eom/content/8/ 1/15.
42. Masterson JT (2004) Enforcement of trademarks and copyright under the WTO agreement on traderelated aspects of intellectual property rights. In: Masterson JT (ed) International trademarks and copyright enforcement and management. American Bar Association Publishing, Chicago, p 1-26.
43. Meitinger I (2005) Implementation of test data protection according to Article 39.3 TRIPS: the search for a fair interpretation of the term 'unfair commercial use'. Journal of World Intellectual Property 8(2):128-130.
44. Moore JW (1998) Patent term restoration for pharmaceutical products in Europe: the supplementary protection certificate. Canadian Intellectual Property Review 14:137-140.
45. Organisation for Economic Co-operation and Development (OECD) (2009) The bioeconomy to 2030: designing a policy agenda. OECD Publishing.
46. Otamendi J (2011) Confidential data in the approval of a 'similar' pharmaceutical product. International Association for the Protection of Intellectual Property e-News 19.
47. Pott A (2011) Opening up data at the EMA: EMA's response to articles. British Medical Journal 342:d3838. doi: 10.1136/bmj.d3838.
48. Pugatch MP (2006) Intellectual property, data exclusivity, innovation and market access. In: Roffe P, Tansey G, Vivas-Eugui D (eds) Negotiating health: intellectual property and access to medicines. Earthscan, London, p 97-132.
49. Reichman JH (2006) The international legal status of undisclosed clinical trial data: from private public goods? In: Roffe P, Tansey G, Vivas-Eugui D (eds) Negotiating health: intellectual property and access to medicines. Earthscan, London, p 133-150.
50. Reichman JH (2009) Rethinking the role of clinical trial data in international intellectual property law: the case for a public goods approach. Marquette Intellectual Property Law Review 13(1):1-68.
51. Schroeder D (2007) Benefit sharing - high time for a definition. Journal of Medical Ethics 33:205-209.
52. Sedyaningsih ER, Isfandari S, Soendoro T, Supari SF (2008) Towards mutual trust, transparency and equity in virus sharing mechanism: the avian influenza case of Indonesia. Annals Academy of Medicine 37(6):482-488.
53. Selker HP, Ruthazer R, Terrin N, Griffith JL, Concannon T, Kent DM (2011) Random treatment assignment using mathematical equipoise for comparative effectiveness trials. Clin Transl Sci 4(1):10-16.
54. Simni K (2007) Benefit-sharing: a look at the history of an ethics concern. Nature 8:496.
55. Tansey G (2006) Introduction: legal fictions and public health. In: Roffe P, Tansey G, Vivas-Eugui D (eds) Negotiating health: intellectual property and access to medicines. Earthscan, London, p 1-7.
56. Taubman A (2008a) The international patent system and biomedical research: reconciling aspiration, policy and practice. The American Association of Pharmaceutical Scientists Journal 10(4):526-536.
57. Taubman A (2008b) Unfair competition and the financing of public-knowledge goods: the problem of test data protection. Journal of Intellectual Property Law & Practice 3(9):591-606.
58. Taubman A (2011) A practical guide to working with TRIPS. Oxford University Press, New York. The European Science Foundation (2009) Forward look - investigator-driven clinical trials, available at http://www.esf.org/ fileadmin/links/EMRC/FL-IDCT.pdf.
59. The National Health Surveillance Agency (ANVISA) and Lundbeck case (2011). World Intellectual Property Review, November/December 29.
60. Thomas K (2012) Medical journal to require more details on drug trials. The New York Times, available at http://www.nytimes.com/2012/11/Ol/ftusiness/ british-medical-journal-to-require-detailed-clinical-trialdata.html?-r=0.
61. Timmermans K (2007) Monopolizing clinical trial data: implications and trends. PLoS Med 4(2):e2. doi: 10.1371/journal.pmed.0040002 at 0206.
62. Walsh B (2007) Indonesia's bird flu showdown. Time Health, May 10, 2007, available at http://www.time.com/time/health/article/0,8599,1619229,00.html.
63. Weissman R (2006) Data protection: options for implementation. In: Roffe P, Tansey G, Vivas-Eugui D (eds) Negotiating health: intellectual property and access to medicines. Earthscan, London. p 151-178.
64. World Health Assembly (2007) Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits. WHA60. 28.
65. World Health Organization (2006a) Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. WHO Technical Report Series 937. available at http://apps.who.int/prequal/info-general/documents/TRS937/WHO-TRS-937-annex7- eng.pdf.
66. World Health Organization (2006b) Public health, innovation and intellectual property rights, report of the commission on intellectual property rights, innovation and public health. Geneva.
67. World Medical Association (2000) Declaration of Helsinki: ethical principles for medical research involving human subjects.
68. World Medical Association (2004) Declaration of Helsinki: ethical principles for medical research involving human subjects.
69. World Medical Association (2008) Declaration of Helsinki: ethical principles for medical research involving human subjects, available at http://www.wma.net/en/30publications/10policies/b3/.
70. Zarin DA, Tse T (2008) Moving toward transparency of clinical trials. Science 319:1340-1342.